MEDLAB Middle East 2020 is a foremost laboratory and flagship exhibition and conference for medical services and devices. MEDLAB is an all-encompassing event for every specialty within the scope of the laboratory management and diagnostics field.
The conference held at the Dubai International Convention and Exhibition Center in Dubai, UAE, provides a platform for education, learn, meet, and create networks with other leading medical services.
EDGC’s promotional booth became a head-turner at the event, hinting that the company may finally enter into the $11.4 billion (13.5 trillion won) worth Middle East healthcare market.
The Incheon-based solutions company introduced healthcare services such as liquid biopsy, personal genome sequencing, customized healthcare products, and molecular prognosis, and non-invasive prenatal test NICE.
EDGC HealthCare and Solgent, a subsidiary of EDGC, jointly prepared the company’s exhibition booth, presenting itself as a “total healthcare provider.”
Over 100,000 participants from 600 companies located in 50 countries were present in the event.
EDGC’s booth attracted over 500 participants interested in the company’s services, inquiring about NICE and liquid biopsy.
“Last year at MEDLAB, EDGC participated alone and only introduced the genome sequencing service,” EDGC Vice President Yoo Jae-hyung said. “But this year, with our subsidiaries, we could present ourselves as the total healthcare service and thus attracted much more attention.”
Last December, EDGC announced during the National Neonatology Forum held in India that it would launch EDGC India along with the Asian country’s Rainbow Children’s Hospital and the Phoenix Group, one of India’s largest conglomerates. According to EDGC, the move would enable the firm to enter India’s $11 billion (13.1 trillion won) worth industry with its service NICE.
The Korean Ministry of Trade and Industry awarded EDGC’s non-invasive prenatal test NICE as one of the winners of the “Korean World-class Product Award 2019.”